Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Brexit Won’t Delay Drug Approvals, EMA’s Rasi Reassures Industry

Executive Summary

The EU’s centralized drug approval process will not be disrupted regardless of the number of employees the European Medicines Agency might lose when it relocates from London to Amsterdam, Guido Rasi pledged yesterday at the DIA Europe 2018 conference.

You may also be interested in...



EMA Redistributes Responsibility For 370 Drugs Currently Overseen By UK

The EMA has completed the reallocation to the EU27 member states of more than 370 centrally authorized drugs for which the UK was rapporteur or co-rapporteur. The move has been necessitated by Brexit, which means the UK will no longer play an active role in new drug evaluations at the EMA.

MEPs Approve EMA Move To Amsterdam, But Insist Deadlines Must Be Met

An EU parliamentary committee has OKd the EMA’s move to Amsterdam, but with caveats. MEPs are unhappy with the way the agency’s new home was decided and have called for changes to the procedure used to choose EU agency locations in future.

High-Stakes Meeting With EMA On The Cards For Oncopeptides’ Pepaxto

Oncopeptides is nearing the end of the regulatory review cycle in the EU for its multiple myeloma drug, melphalan flufenamide. The product has had an erratic journey in the US, where it was approved but then withdrawn, and the withdrawal was subsequently rescinded.

Topics

UsernamePublicRestriction

Register

PS122922

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel